HoldsUp

Michael Snyder

Stanford University

Michael Snyder is the chair of the Department of Genetics and director of the Center for Genomics and Personalized Medicine at Stanford University. His work focuses on personalized medicine, big data, and deep profiling using wearable technology. His published research covers multi-omics analysis, single-cell genomics and proteomics, continuous glucose monitoring, and transcriptomic regulation in human disease.

30 claims checked on air: 2 context 1 contradicted 1 overstated 26 supported 2 flagged

What they said on air - flagged

0:07:34contradictedhighDr. Michael Snyder on Continuous Glucose Monitoring and Deep

Fasting glucose is typically targeted at 90 mg/dL or below, levels over 120 mg/dL classify type 2 diabetes, and values between those define pre-diabetes.

"normally people want to have their glucose at 90 or below. But, um, and when it gets over 120, then you're typically classified as type 2 diabetic, and so in between is typically called pre-diabetes." (said at 0:07:34)

The diagnostic thresholds stated by the speaker contradict established medical diagnostic criteria for diabetes and prediabetes. Standard diagnostic guidelines define diabetes as a fasting plasma glucose (FPG) level of 126 mg/dL or higher (≥126 mg/dL), not >120 mg/dL. Prediabetes (impaired fasting glucose) is clinically defined as fasting glucose levels between 100 mg/dL and 125 mg/dL, not between 90 mg/dL and 120 mg/dL. Normal fasting plasma glucose extends up to 99 mg/dL (<100 mg/dL).

1:01:50overstatedmoderateDr. Michael Snyder on Continuous Glucose Monitoring and Deep

Following antibiotic use, the gut microbiome shifts but generally bounces back to its baseline composition after cessation of the antibiotic.

"If you take an antibiotic, you'll shift it, but then it bounces right back, believe it or not, as soon as you go off the antibiotic." (said at 1:01:50)

While the gut microbiome possesses ecological resilience and often shifts back toward baseline composition following antibiotic cessation, recovery is not immediate and is frequently incomplete. Prospective human studies demonstrate that recovery to near-baseline composition typically requires weeks to months, rather than occurring immediately upon stopping the drug. Furthermore, recovery trajectories vary substantially depending on the antibiotic class, baseline microbiome composition, and host factors; certain taxa may remain permanently depleted or undetectable for months, and antibiotic resistance genes can persist long after treatment ends.

Fact-checked episodes

Publications